Reading PHR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PHR free→
Phreesia, Inc. (PHR)
NYSEHealth CareHealth Information ServicesSnapshot 2026-06-16
Intact
$9.14+0.94%
Close 2026-06-15 · 1-day change
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
The bottom line
Recent financial performance is strong, and earnings quality is robust, cash backs up reported profits. Management's recent track record has been fairly steady, but risk is high, and the sector backdrop is a headwind. Peer multiples imply a price about 26% above where it trades (it looks cheap on this basis); the read is fair, quality intact. Key factors to watch include guidance changes and sector trends, as these could significantly impact estimates and stock performance. This read is provisional.
as of 2026-06-16
Quick facts
- Exchange
- NYSE
- Sector
- Health Care
- Industry
- Health Information Services
- Market cap
- $559.67M
- Employees
- 1,733
- IPO date
- 2019-06-21
- Next earnings
- —
Price
Daily closes. Earnings/event dots are placed inline.
Adjusted daily closes (split & dividend). Scroll over the chart to zoom; click a range to reset.
EarningsMaterial event
What's priced in
(what the market already expects)What it's worth (estimated)
A consensus fair price across 6 valuation methods, at three horizons. Current price $9.14. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
12-month· primaryfair
$12.31consensus
Range $11.25 – $14.88
vs price: -23% below
Method agreement — · 6 methods
No-growth: today's peer multiple on trailing earnings. The headline read.
3-yearinexpensive
$33.94consensus
Range $25.71 – $42.17
vs price: -72% below
Method agreement — · 2 methods
Embeds projected growth. Leans optimistic by design. Upside context.
5-yearinexpensive
How much to trust our fair value
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
Cheap vs peersmedium confidence
At $9.14 PHR trades at 13× p/e, below its 15× p/e peer median. Our $12 fair value sits above the price; medium confidence. Analysts: $9.00–$16. Not investment advice.
Multiple (P/E)
12.9x
peer 14.7x · own history —
Premium
0.9x peer
Growth the price needs
-23%
our forecast 17%
Our fair value
$11.92
range $10.64 – $14.33
Analyst range(a guide on our number, not a target)Our number is in the analyst range
How this stock is priced
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Long-term · 1–3 yr
fairfair — quality intact12-month view
What's priced inJustified
The price implies about 23% below a flat-multiple fair value, below our forecast of about 17%. This describes what's priced in, not a forecast of the move.
Low fragilityrisk posture, not a price call
Only a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
Historical context
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
How strong is the business
(quality & execution)Factor signals
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Recent financial performance
strongOperating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
78th pctl · Health Care
Earnings quality
robustOver the trailing year it converted 9.57x of net income into operating cash flow. Historically, Health Care names rated robust grew net income 60% of the time over the next year (vs 48% for the rest of the cohort, n=1703).
95th pctl · Health Care
Macro sensitivity
Most sensitive to the broad stock market.
- the broad stock market: This stock moves with the broad market (high beta).
Not enough signal to read sensitivity to the US dollar, long-term interest rates, Fed net liquidity, real (inflation-adjusted) rates.
Management & capital allocation
Earnings setup & market context
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
Earnings setup · pre-print positioning
forward-looking
Neutral5 PT revisions / 30d, avg 34.3% above currentfor period ending 2026-07-31
Why this setup
Consensus revisions
EPS estimate $0.33 → $0.32 (-2.1% / 30d). 5 raised, 3 cut, 10 covering analysts.
Rating actions
0 upgrades, 1 downgrade / 30d, 4 maintained. 60% of analysts rate Buy.
Price target activity
5 PT revisions / 30d. Avg target 34.3% above current price.
Material events
0 positive, 1 negative / 30d. See F4 management tile for the event list.
Sector context
Intermediate · WeeklySector phase: health care is in (~0.5 years in phase).
Management scorecard
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Long-term · 1–3 yr
Overall: neutral
- Capital allocation
- neutral
- Earnings discipline
- neutral
- Margin discipline
- neutral
- Balance sheet
- weak
- Post-call reaction
- strong
A guidance track record builds as the company issues and delivers on guidance.
as of 2026-06-15
How bumpy is the path
(risk while you hold it)Risk: how this stock moves
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
Intermediate · WeeklyLong-term · 1–3 yr
On a typical day, $10k can swing ±$158.
How much price usually moves either way.
On a bad day, this stock has moved -$519.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $7,524.
Deepest peak-to-trough drop in the last year.
highas of 2026-06-16
Past results, not a forecast. Not investment advice.
What would change the read
(catalysts & re-read triggers)What changed
The most important moves since the prior daily snapshot.
Short-term · Daily
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
What to watch next
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Intermediate · Weekly
- UpsideMedium confidenceQuartersactive 4d
Watch for sector revenue growth speeding up again.
Why it matters: If revenue growth picks up, it could indicate a positive shift for Phreesia's market.
What confirms / what disproves
Confirms:3-year revenue growth in the health care sector rises above 12 percent.
Disproves:3-year revenue growth in the health care sector stays below 10 percent.
Sector context
News catalysts
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for PHR yet.
This sector is also watching
- Watch for revenue growth re-acceleration in Health Care
What could change this view
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Intermediate · Weekly
Upside triggers
- If sector bellwethers like VEEV, BTSG, and TEM keep beating earnings and guiding higher, the Healthcare sector momentum should keep lifting PHR and other Healthcare names. Worth watching these names for early signals.
- If PHR raises forward guidance on the next earnings call (currently NEW as of 2026-05-27), that's a momentum boost. Street estimates typically follow guidance up and the stock tends to re-rate higher.
Downside triggers
- If PHR cuts guidance on the next call (currently NEW as of 2026-05-27), that's a meaningful negative. The Street tends to walk down estimates and the stock usually takes a leg lower.
- If sector bellwethers like VEEV, BTSG, and TEM start missing or guiding lower, the Healthcare tailwind helping PHR and other Healthcare names could fade. Watch these names for early warning.
- If PHR misses again next quarter like this past one (a big miss of -35% on the 2026-04-30 print), expect continued pressure. The Street usually keeps walking estimates down after consecutive misses.
Recent events
(material 8-K / filing activity)Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-2721d agoItem 2.02
Results of Operations and Financial Condition On May 27, 2026, Phreesia, Inc. (the “Company”) announced its financial results for the fiscal first quarter ended April 30, 2026 by issuing a stakeholder letter (the "Letter") and a press release. Copies of the press release and the Letter are furnished as Exhibits 99.1 and 99.2, respectively, to this Current Report on Form 8-K and are incorporated by reference herein. The information furnished under this
Earnings preannouncementnegative
Score history
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
-9.6 vs last weeklatest as of 2026-06-17
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.